Itzhak Krinsky Operating Director

  • EducationTel Aviv University
    McMaster University
  • ExperienceTeva Pharmaceutical Industries
    Kamada Ltd.
    Concordia Healthcare
    Bankers Trust
    Deutsche Bank
  • Board RolesNoramco

Prof. (Emeritus) Itzhak Krinsky, Ph.D., has worked with SK Capital Partners since 2017. He currently serves as a director and member of the audit committee of Globrands Ltd., Noramco Inc., Woodstock Sterile Solutions, PolyPid, and Apotex.

Prof. Krinsky joined Teva Pharmaceutical Industries, Ltd. in 2005 and served as an Executive Vice President, Corporate Business Development as well as a member of the Teva Executive Committee from 2005 to 2014.  He was an active Chairman of Teva Japan, Chairmen of Teva S. Korea, and Head of Business Development Asia Pacific. He also served as a director at Kamada Ltd. and Concordia Healthcare. In 2014, SCRIP, one of the most prestigious pharmaceutical media outlets, selected Prof. Krinsky as one of the 100 Global Leaders of the industry. Prior to joining Teva, he held various senior positions in investment banks in New York City including with Bankers Trust and Deutsche Bank.

Prior to his tenure on Wall Street, Prof. Krinsky had a distinguished academic career as a Professor of Finance & Business Economics at the Michael G. DeGroote School of Business, McMaster University, Canada. Prof. Krinsky has published more than 80 articles in leading peer reviewed academic journals. He holds a BA and MA in Economics from Tel Aviv University, Israel & a Ph.D. in Economics from McMaster University, Ontario Canada.

Operating Directors are not employees of SK Capital. Such directors are expected to receive compensation from certain Funds’ portfolio investments and/or directly from certain Funds. Such compensation will not result in offsets to, or reductions of the management fee paid by the corresponding Fund.